Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee...








    



            







    
        
            February 13, 2026 08:30 ET
        

        
             | Source:
            

                Profusa, Inc.
            
                

        
    

    

    

    





        
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product   Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications  BERKELEY, Calif, Feb.  13, 2026  (GLOBE NEWSWIRE) --  Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual’s biochemistry, has entered into a know-how agreement with Mayo Clinic.  The collaboration entails investigation of high impact clinical applications of Profusa’s oxygen monitoring technologies for new product development and commercialization.  Potential target indications include cardiovascular, renal, multi-organ, and orthopedic applications, among others, where intra-organ postoperative perfusion monitoring has potential to improve clinical outcomes. The collaboration also supports Profusa’s potential commercialization of Lumee oxygen sensing and tissue monitoring technology for chronic limb threatening ischemia (CLTI) in the U.S.  Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic, Rochester, Minn., said, “Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure. Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue.”  “Following more than a decade of development and over $100 million in investment, our Lumee technology enables continuous, real-time measurement of tissue oxygen directly within the body, which we believe to be a first-of-its-kind, disruptive biochemistry monitoring platform. In addition, we are committed to continue to harness our platform technology for innovative solutions that seek to both address large unmet clinical needs and reduce costs for healthcare systems through earlier detection and improved disease management.  We look forward to collaborating with Mayo Clinic for the U.S. commercialization of Lumee for chronic limb threatening ischemia and developing products to address new indications to expand our oxygen tissue monitoring technology’s market and therapeutic reach,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO.  Mayo Clinic has a financial interest in the technology referenced in this press release.  Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.  About Profusa  Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.  “LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.  For more information, visit https://profusa.com.  Special Note Regarding Forward-Looking Statements  Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.  Contacts  Investor and Media Contactsemail:  info@coreir.comphone:  1 (212) 655-0924  
            

PFSA

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Profusa, Inc. has entered a collaboration with Mayo Clinic aimed at expediting the regulatory approval and commercialization of its Lumee wearable oxygen monitoring system. This partnership targets potential applications in areas like chronic limb threatening ischemia, which could significantly enhance patient outcomes and expand the market reach for Profusa&#039;s technology.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Profusa partners with Mayo Clinic for Lumee oxygen monitoring product.</li><li>Collaboration targets commercialization for chronic limb threatening ischemia.</li><li>New technologies may enhance post-surgery monitoring and outcomes.</li><li>Profusa has invested over $100 million in Lumee development.</li><li>Mayo Clinic has a financial stake in this technology.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Mayo Clinic (N/A)</strong>: Financial interest in Lumee technology may support future developments.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under &#039;Corporate Developments&#039; as it marks a significant collaboration aimed at expanding product marketability and clinical application. Collaborations with prestigious institutions like Mayo Clinic can significantly enhance credibility and accelerate product validation in the healthcare sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA approval of Lumee could significantly boost PFSA&#039;s market valuation.</li><li>Successful market entry into chronic limb threatening ischemia may lead to accelerated revenues.</li><li>Mayo Clinic&#039;s financial interest could enhance product credibility, potentially driving stock demand.</li><li>Expansion into new clinical applications could further increase the company&#039;s addressable market.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Profusa has invested over $100 million in Lumee development.</li><li>Collaboration with Mayo Clinic announced on February 13, 2026.</li><li>Lumee targets chronic limb threatening ischemia and other clinical applications.</li><li>Dr. Michael Kendrick emphasizes the importance of tissue oxygen in surgical recovery.</li><li>Profusa is focused on continuous, real-time monitoring of tissue oxygen.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy PFSA to capitalize on potential regulatory approval and market expansion over the next 12-24 months.</p>
  </section>
</section>


<article>
  <header>
    <h1>Profusa Partners with Mayo Clinic to Enhance Oxygen Monitoring Technologies</h1>
    <p><strong>BERKELEY, Calif., February 13, 2026 (GLOBE NEWSWIRE)</strong> — Profusa, Inc. (Nasdaq: <strong>PFSA</strong>), a leading digital health company specializing in continuous biochemical monitoring, has announced a collaboration with Mayo Clinic aimed at accelerating the regulatory approval and commercialization of its innovative Lumee™ continuous tissue oxygen monitoring product.</p>
  </header>

  <section>
    <h2>Goals of the Collaboration</h2>
    <p>The primary objective of this partnership is to explore high-impact clinical applications for Profusa’s oxygen monitoring technologies. This includes the development and commercialization of new tethered continuous oxygen monitoring products targeting several key areas:</p>
    <ul>
      <li>Cardiovascular applications</li>
      <li>Renal indications</li>
      <li>Multi-organ monitoring</li>
      <li>Orthopedic interventions</li>
    </ul>
    <p>Specifically, this collaboration will enhance Profusa’s potential to commercialize Lumee technology for chronic limb threatening ischemia (CLTI) in the U.S., significantly improving clinical outcomes through intra-organ postoperative perfusion monitoring.</p>
  </section>

  <section>
    <h2>Insights from Medical Experts</h2>
    <p>Michael Kendrick, M.D., Chair of the Department of Surgery at Mayo Clinic in Rochester, Minnesota, emphasized the importance of oxygen in cellular metabolism and tissue repair. He stated, <em>“Oxygen is essential for cellular metabolism and tissue repair, with a lack of sufficient oxygenation impairing wound healing and increasing the risk of complications common to surgery.”</em> The collaboration offers an opportunity to leverage Profusa’s innovative platform to better address unmet clinical challenges by monitoring beyond subcutaneous tissue.</p>
  </section>
  
  <section>
    <h2>Profusa’s Technological Advances</h2>
    <p>Profusa's Chairman and CEO, Ben Hwang, Ph.D., highlighted that after over a decade of development and more than <strong>$100 million</strong> in investment, Lumee technology is positioned as a <em>first-of-its-kind</em> biochemical monitoring platform. Dr. Hwang stated, <em>“We are committed to harnessing our platform to address large unmet clinical needs while reducing healthcare costs through earlier detection and improved disease management.”</em> This partnership is expected to expand the market reach of Profusa’s oxygen tissue monitoring technology.</p>
  </section>

  <section>
    <h2>About Profusa</h2>
    <p>Headquartered in Berkeley, California, Profusa is transforming healthcare with its advanced technology in tissue-integrated sensors that provide continuous monitoring of actionable medical data. The company's goal is to offer affordable, long-lasting injectable biosensors paired with an intelligent data platform that generates reliable biochemical signatures for clinicians.</p>
  </section>

  <section>
    <h2>Forward-Looking Statements</h2>
    <p>This announcement contains forward-looking statements regarding future events and the operational performance of Profusa. As defined under the United States Private Securities Litigation Reform Act, these statements involve inherent risks and uncertainties, which may cause actual results to differ materially from those projected. Interested parties are encouraged to review Profusa's filings with the SEC for a detailed discussion of these risks.</p>
  </section>

  <footer>
    <p>For more information on Profusa and its innovations, visit <a href="https://profusa.com">profusa.com</a>.</p>
    <p><strong>Investor and Media Contacts:</strong>
      <br>Email: info@coreir.com
      <br>Phone: 1 (212) 655-0924
    </p>
  </footer>
</article>

Profusa, Inc. has entered a collaboration with Mayo Clinic aimed at expediting the regulatory approval and commercialization of its Lumee wearable oxygen monitoring system. This partnership targets potential applications in areas like chronic limb threatening ischemia, which could significantly enhance patient outcomes and expand the market reach for Profusa's technology.

Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News